Vertex Pharma (VRTX): Kalydeco Miss Is Not A Game Changer - Jefferies

August 16, 2016 7:31 AM EDT
Get Alerts VRTX Hot Sheet
Price: $81.55 -1.95%

Rating Summary:
    24 Buy, 17 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 35 | Down: 31 | New: 11
Trade VRTX Now!
Join SI Premium – FREE

Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.

Jefferies analyst, Brian Abrahams, reiterated his Buy rating on shares of Vertex (NASDAQ: VRTX) after the company announced that '661/Kalydeco missed on its interim efficacy analysis in het/min CF patients.

Success would have created an opportunity to reach this large subpopulation with the dual combo and reaffirmed '661's activity (given its importance as a backbone for the triple). However, the analyst believes expectations were low, and the event does not change his overall positive CF franchise view.

No change to the price target of $107.

For an analyst ratings summary and ratings history on Vertex click here. For more ratings news on Vertex click here.

Shares of Vertex closed at $102.48 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, Analyst EPS View, FDA

Related Entities

Jefferies & Co

Add Your Comment